Rimonabant (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rimonabant" in Serbian language version.

refsWebsite

Global rank Serbian rank

4web.archive.org

1^st place

1^st place

4^th place

8^th place

2^nd place

4^th place

68^th place

107^th place

8^th place

16^th place

1acompliareport.com

low place

low place

1sanofi-aventis.com

low place

low place

acompliareport.com

„Zimulti Acomplia Report - Diet Drug Acomplia / Zimulti Gets Thumbs Down From FDA Panel”. Acompliareport.com. 13. 06. 2007. Архивирано из оригинала 13. 09. 2009. г. Приступљено 19. 03. 2010.

bbc.co.uk

news.bbc.co.uk

„Anti-obesity drug use suspended”. BBC News. 23. 10. 2008. Приступљено 4. 3. 2010.

doi.org

Fong TM, Heymsfield SB (2009). „Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions”. Int J Obes (Lond). 33 (9): 947—55. PMID 19597516. doi:10.1038/ijo.2009.132.
Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. (1989). „Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation”. Journal of Medicinal Chemistry. 32 (2): 421. PMID 2913302. doi:10.1021/jm00122a022.

europa.eu

emea.europa.eu

„European Medicines Agency”. Emea.europa.eu. 15. 02. 2010. Архивирано из оригинала 15. 07. 2013. г. Приступљено 19. 03. 2010.
„Microsoft Word - Zimulti _Rimonabant_ Public Statement” (PDF). Архивирано из оригинала (PDF) 26. 12. 2009. г. Приступљено 19. 03. 2010.

nih.gov

ncbi.nlm.nih.gov

Fong TM, Heymsfield SB (2009). „Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions”. Int J Obes (Lond). 33 (9): 947—55. PMID 19597516. doi:10.1038/ijo.2009.132.
Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. (1989). „Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation”. Journal of Medicinal Chemistry. 32 (2): 421. PMID 2913302. doi:10.1021/jm00122a022.

sanofi-aventis.com

en.sanofi-aventis.com

„Sanofi-aventis - A diversified healthcare company, focused on patients’ needs”. En.sanofi-aventis.com. Архивирано из оригинала 07. 05. 2011. г. Приступљено 19. 03. 2010.

web.archive.org

„Zimulti Acomplia Report - Diet Drug Acomplia / Zimulti Gets Thumbs Down From FDA Panel”. Acompliareport.com. 13. 06. 2007. Архивирано из оригинала 13. 09. 2009. г. Приступљено 19. 03. 2010.
„European Medicines Agency”. Emea.europa.eu. 15. 02. 2010. Архивирано из оригинала 15. 07. 2013. г. Приступљено 19. 03. 2010.
„Sanofi-aventis - A diversified healthcare company, focused on patients’ needs”. En.sanofi-aventis.com. Архивирано из оригинала 07. 05. 2011. г. Приступљено 19. 03. 2010.
„Microsoft Word - Zimulti _Rimonabant_ Public Statement” (PDF). Архивирано из оригинала (PDF) 26. 12. 2009. г. Приступљено 19. 03. 2010.